Amedeo Smart

Free Medical Literature Service


 

Amedeo

Peptic Ulcer

  Free Subscription

Articles published in
Aliment Pharmacol Ther
    March 2024
  1. KRAUSE AJ, Yadlapati R
    Review article: Diagnosis and management of laryngopharyngeal reflux.
    Aliment Pharmacol Ther. 2024;59:616-631.
    >> Share

    February 2024
  2. YOON JS, Hong JH, Park SY, Kim SU, et al
    High-dose proton pump inhibitor treatment is associated with a higher mortality in cirrhotic patients: A multicentre study.
    Aliment Pharmacol Ther. 2024 Feb 22. doi: 10.1111/apt.17909.
    >> Share

  3. LON N, Engel S, Damholt A, Mortensen B, et al
    Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage: A randomised, double blind, placebo-controlled crossover trial.
    Aliment Pharmacol Ther. 2024;59:341-349.
    >> Share

    August 2023
  4. GONG EJ, Jung HK, Lee B, Hong J, et al
    Proton pump inhibitor use and the risk of metachronous gastric cancer after H. pylori eradication in patients who underwent endoscopic resection for gastric neoplasms: A population-based cohort study.
    Aliment Pharmacol Ther. 2023 Aug 17. doi: 10.1111/apt.17676.
    >> Share

    July 2023
  5. WAUTERS L, Harris PR, Walker MM, Serrano CA, et al
    Letter: childhood recurrent abdominal pain is associated with increased duodenal eosinophilia independent of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2023;58:134-136.
    >> Share

    May 2023
  6. PIOVANI D, Tsantes AG, Schunemann HJ, Bonovas S, et al
    Letter: Potassium-competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication-a retrospective multicentre-cohort analysis. Authors' reply.
    Aliment Pharmacol Ther. 2023;57:1199-1200.
    >> Share

  7. KOUNTOURAS J, Papaefthymiou A, Polyzos SA, Kazakos E, et al
    Letter: higher severe outcomes among Helicobacter pylori-related lean patients with non-alcoholic fatty liver disease and metabolic comorbidities.
    Aliment Pharmacol Ther. 2023;57:1186-1187.
    >> Share

  8. ARAI J, Hayakawa Y, Niikura R, Ihara S, et al
    Letter: Potassium-competitive acid blockers may increase the risk of gastric cancer after Helicobacter pylori eradication a retrospective multicentre-cohort analysis.
    Aliment Pharmacol Ther. 2023;57:1196-1198.
    >> Share

    April 2023
  9. HOWDEN CW, Shah S, Pendse SN, Offman E, et al
    Physiologically based pharmacokinetic modelling to predict intragastric rifabutin concentrations in the treatment of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2023 Apr 20. doi: 10.1111/apt.17526.
    >> Share

  10. SCARPIGNATO C, Howden CW, Leifke E, Mulford DJ, et al
    A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2023 Apr 17. doi: 10.1111/apt.17510.
    >> Share

    March 2023
  11. TAILLIEU E, De Witte C, De Schepper H, Van Moerkercke W, et al
    Clinical significance and impact of gastric non-Helicobacter pylori Helicobacter species in gastric disease.
    Aliment Pharmacol Ther. 2023 Mar 28. doi: 10.1111/apt.17488.
    >> Share

    January 2023
  12. POMENTI S, Katzka DA
    Editorial: P-CABs for treatment of reflux oesophagitis-is this the future?
    Aliment Pharmacol Ther. 2023;57:146-147.
    >> Share

    December 2022
  13. PIOVANI D, Tsantes AG, Schunemann HJ, Bonovas S, et al
    Meta-analysis: Use of proton pump inhibitors and risk of gastric cancer in patients requiring gastric acid suppression.
    Aliment Pharmacol Ther. 2022 Dec 31. doi: 10.1111/apt.17360.
    >> Share

  14. HUI S, Lim A, Koh E, Abasszade J, et al
    Prevalence and prognostic significance of vitamin C deficiency in patients with acute upper gastrointestinal bleeding: a prospective cohort study.
    Aliment Pharmacol Ther. 2022 Dec 13. doi: 10.1111/apt.17359.
    >> Share

    October 2022
  15. CHO YK, Kim JH, Kim HS, Kim TO, et al
    Randomised clinical trial: comparison of tegoprazan and lansoprazole as maintenance therapy for healed mild erosive oesophagitis.
    Aliment Pharmacol Ther. 2022 Oct 31. doi: 10.1111/apt.17255.
    >> Share

  16. YADLAPATI R, Gawron AJ, Gyawali CP, Chen J, et al
    Clinical role of ambulatory reflux monitoring in PPI non-responders: recommendation statements.
    Aliment Pharmacol Ther. 2022;56:1274-1283.
    >> Share

    September 2022
  17. ANG D, Koo SH
    Editorial: slow progress to optimising H. pylori eradication treatment with antisecretory drugs-authors' reply.
    Aliment Pharmacol Ther. 2022;56:1076-1077.
    >> Share

  18. GISBERT JP, Hunt RH
    Editorial: slow progress to optimising H. pylori eradication treatment with antisecretory drugs.
    Aliment Pharmacol Ther. 2022;56:1074-1075.
    >> Share

    August 2022
  19. RAYMENANTS K, Tack J
    Editorial: refractory reflux sensitivity-A place for baclofen? Authors' reply.
    Aliment Pharmacol Ther. 2022;56:725-726.
    >> Share

  20. KATZ PO
    Editorial: refractory reflux sensitivity - a place for baclofen?
    Aliment Pharmacol Ther. 2022;56:723-724.
    >> Share

  21. ANG D
    Letter: a promising Helicobacter pylori regimen-vonoprazan-based therapy. Author's reply.
    Aliment Pharmacol Ther. 2022;56:754-755.
    >> Share

  22. HU Y, Lu NH
    Letter: a promising Helicobacter pylori regimen - vonoprazan-based therapy.
    Aliment Pharmacol Ther. 2022;56:752-753.
    >> Share

    July 2022
  23. YEOMANS ND
    Editorial: risk of gastric and duodenal ulcers among new users of low-dose aspirin.
    Aliment Pharmacol Ther. 2022;56:334-335.
    >> Share

  24. RADADIYA D, Devani K, Rockey DC
    Editorial: the impact of red blood cell transfusion on inpatient mortality in upper gastrointestinal bleeding-authors' reply.
    Aliment Pharmacol Ther. 2022;56:338-339.
    >> Share

  25. ORPEN-PALMER J, Stanley AJ
    Editorial: the impact of red blood cell transfusion on inpatient mortality in upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2022;56:336-337.
    >> Share

    June 2022
  26. ANG D, Koo SH, Chan YH, Tan TY, et al
    Clinical trial: seven-day vonoprazan- versus 14-day proton pump inhibitor-based triple therapy for first-line Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2022 Jun 3. doi: 10.1111/apt.17070.
    >> Share

  27. PAUWELS A, Raymenants K, Geeraerts A, Boecxstaens V, et al
    Clinical trial: a controlled trial of baclofen add-on therapy in PPI-refractory gastro-oesophageal reflux symptoms.
    Aliment Pharmacol Ther. 2022 Jun 3. doi: 10.1111/apt.17068.
    >> Share

  28. SONNENBERG A
    Letter: birth cohort pattern of Helicobacter pylori infection rates.
    Aliment Pharmacol Ther. 2022;55:1461.
    >> Share

  29. CHEN S, Liu D, Chen H, Liao A, et al
    The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.
    Aliment Pharmacol Ther. 2022;55:1524-1533.
    >> Share

    May 2022
  30. NGUYEN TNM, Sha S, Chen LJ, Holleczek B, et al
    Strongly increased risk of gastric and duodenal ulcers among new users of low-dose aspirin: Results from two large cohorts with new-user design.
    Aliment Pharmacol Ther. 2022 May 27. doi: 10.1111/apt.17050.
    >> Share

    February 2022
  31. JIANG F, Guo CG, Leung WK
    Letter: the hidden reasons of long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication-authors' reply.
    Aliment Pharmacol Ther. 2022;55:374-375.
    >> Share

  32. YANG H, Hu B
    Letter: the hidden reasons of long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2022;55:372-373.
    >> Share

    January 2022
  33. ZHENG X, Li N, Zhao J
    Letter: proton pump inhibitors and risk of myocardial infarction.
    Aliment Pharmacol Ther. 2022;55:139-140.
    >> Share

  34. NOLDE M, Ahn N, Dreischulte T, Ruckert-Eheberg IM, et al
    Letter: proton pump inhibitors and risk of myocardial infarction-authors' reply.
    Aliment Pharmacol Ther. 2022;55:141-142.
    >> Share

  35. YANG JC, Kao JY
    Treatment considerations in Helicobacter pylori management.
    Aliment Pharmacol Ther. 2022;55 Suppl 1:S22-S28.
    >> Share

  36. DORE MP, Graham DY
    Modern approach to the diagnosis of Helicobacter pylori infection.
    Aliment Pharmacol Ther. 2022;55 Suppl 1:S14-S21.
    >> Share

  37. SONNENBERG A
    Epidemiology of Helicobacter pylori.
    Aliment Pharmacol Ther. 2022;55 Suppl 1:S1-S13.
    >> Share

    November 2021
  38. SUGANO K, Howden CW
    Editorial: the never-ending story-Helicobacter pylori and peptic ulcer disease.
    Aliment Pharmacol Ther. 2021;54:1350-1351.
    >> Share

  39. JIANG F, Guo CG, Leung WK
    Editorial: the never-ending story-Helicobacter pylori and peptic ulcer disease. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:1352-1353.
    >> Share

    October 2021
  40. SCHUITENMAKER JM, Oude Nijhuis RAB, Bredenoord AJ
    Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:976.
    >> Share

  41. RIBOLSI M, Savarino E
    Letter: is wireless oesophageal pH monitoring the best technique to evaluate night-time reflux?
    Aliment Pharmacol Ther. 2021;54:974-975.
    >> Share

    September 2021
  42. JIANG F, Guo CG, Cheung KS, Leung WK, et al
    Long-term risk of upper gastrointestinal bleeding after Helicobacter pylori eradication: a population-based cohort study.
    Aliment Pharmacol Ther. 2021 Sep 16. doi: 10.1111/apt.16604.
    >> Share

  43. NOLDE M, Ahn N, Dreischulte T, Ruckert-Eheberg IM, et al
    The long-term risk for myocardial infarction or stroke after proton pump inhibitor therapy (2008-2018).
    Aliment Pharmacol Ther. 2021 Sep 3. doi: 10.1111/apt.16565.
    >> Share

  44. BASNAYAKE C, Geeraerts A, Pauwels A, Koek G, et al
    Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, oesophageal lesions and treatment.
    Aliment Pharmacol Ther. 2021;54:755-778.
    >> Share

    August 2021
  45. ZAMANI M, Alizadeh-Tabari S, Hasanpour AH, Eusebi LH, et al
    Systematic review with meta-analysis: association of Helicobacter pylori infection with gastro-oesophageal reflux and its complications.
    Aliment Pharmacol Ther. 2021 Aug 26. doi: 10.1111/apt.16585.
    >> Share

  46. ARAI J, Aoki T, Hayakawa Y, Niikura R, et al
    Letter: predictive model for gastric cancer after eradication of Helicobacter pylori-a survival analysis using a deep learning algorithm.
    Aliment Pharmacol Ther. 2021;54:528-529.
    >> Share

  47. LIU Y, Chen M
    Letter: association between the risk of microscopic colitis and use of proton pump inhibitors.
    Aliment Pharmacol Ther. 2021;54:526-527.
    >> Share

  48. CHEN L, Glance S, Garg M
    Letter: response of eosinophilic oesophagitis to proton pump inhibitor therapy-the importance of biopsies at index endoscopy.
    Aliment Pharmacol Ther. 2021;54:521-522.
    >> Share

  49. LUI TKL, Leung WK
    Letter: predictive model for gastric cancer after eradication of Helicobacter pylori-a survival analysis using a deep learning algorithm. Authors' reply.
    Aliment Pharmacol Ther. 2021;54:530-531.
    >> Share

  50. KATZ P
    Editorial: non-erosive reflux disease is often not GERD-time to change the definition or abandon the term?
    Aliment Pharmacol Ther. 2021;54:493-494.
    >> Share

    July 2021
  51. KIM YD, Wang J, Shibli F, Poels KE, et al
    No association between chronic use of ranitidine, compared with omeprazole or famotidine, and gastrointestinal malignancies.
    Aliment Pharmacol Ther. 2021 Jul 12. doi: 10.1111/apt.16464.
    >> Share

  52. ROGERS BD, Gyawali CP
    Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers?
    Aliment Pharmacol Ther. 2021;54:188-189.
    >> Share

  53. FRAZZONI M, Frazzoni L, de Bortoli N, Savarino E, et al
    Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers? Authors' reply.
    Aliment Pharmacol Ther. 2021;54:190-191.
    >> Share

  54. OUDE NIJHUIS RAB, Sweis R, Abdul-Razakq H, Schuitenmaker JM, et al
    Characterisation of patients with supine nighttime reflux: observations made with prolonged wireless oesophageal pH monitoring.
    Aliment Pharmacol Ther. 2021;54:144-152.
    >> Share

    June 2021
  55. RIBOLSI M, Frazzoni M, Marabotto E, De Carlo G, et al
    Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus.
    Aliment Pharmacol Ther. 2021 Jun 28. doi: 10.1111/apt.16481.
    >> Share

  56. SALVO EM, Ferko NC, Cash SB, Gonzalez A, et al
    Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors.
    Aliment Pharmacol Ther. 2021 Jun 11. doi: 10.1111/apt.16407.
    >> Share

  57. YADAV Y, Talley NJ
    Editorial: microscopic colitis linked to NSAIDs but not proton pump inhibitors.
    Aliment Pharmacol Ther. 2021;53:1324-1325.
    >> Share

    April 2021
  58. FRAZZONI M, Frazzoni L, De Bortoli N, Russo S, et al
    Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance-pH parameters implying anti-reflux mechanism of action.
    Aliment Pharmacol Ther. 2021 Apr 15. doi: 10.1111/apt.16371.
    >> Share

    March 2021
  59. EUSEBI LH, Telese A, Cirota GG, Haidry R, et al
    Systmatic review with meta-analysis: Risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms.
    Aliment Pharmacol Ther. 2021 Mar 11. doi: 10.1111/apt.16321.
    >> Share

  60. HUSSAIN N, Shung DL
    Editorial: vitamin K antagonists versus direct oral anticoagulants in upper gastrointestinal bleeding.
    Aliment Pharmacol Ther. 2021;53:751-752.
    >> Share

  61. LABENZ C, Schattenberg JM
    Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:673.
    >> Share

  62. SUGIYAMA T
    Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view.
    Aliment Pharmacol Ther. 2021;53:671-672.
    >> Share

  63. ROCCO A, Compare D, Sgamato C, Coccoli P, et al
    Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzle. Authors' reply.
    Aliment Pharmacol Ther. 2021;53:665-666.
    >> Share

  64. CELSA C, Camma C
    Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzle.
    Aliment Pharmacol Ther. 2021;53:663-664.
    >> Share

    February 2021
  65. ABDEL-AZIZ Y, Metz DC, Howden CW
    Review article: potassium-competitive acid blockers for the treatment of acid-related disorders.
    Aliment Pharmacol Ther. 2021 Feb 16. doi: 10.1111/apt.16295.
    >> Share

    January 2021
  66. LEUNG WK, Cheung KS, Li B, Law SYK, et al
    Applications of machine learning models in the prediction of gastric cancer risk in patients after Helicobacter pylori eradication.
    Aliment Pharmacol Ther. 2021 Jan 24. doi: 10.1111/apt.16272.
    >> Share

  67. GOURIOU C, Bouguen G, Lahmek P, Pelaquier A, et al
    Outcomes of upper gastrointestinal bleeding are similar between direct oral anticoagulants and vitamin K antagonists.
    Aliment Pharmacol Ther. 2021 Jan 5. doi: 10.1111/apt.16236.
    >> Share

    December 2020
  68. ROCCO A, Compare D, Sgamato C, Coccoli P, et al
    Impact of proton pump inhibitors on cytochrome P450 activity assessed by (13) C-aminopyrine breath test in patients with cirrhosis.
    Aliment Pharmacol Ther. 2020 Dec 28. doi: 10.1111/apt.16239.
    >> Share

    November 2020
  69. CHAUDHARY S, Mackay D, Pell JP, Morris J, et al
    Upper gastrointestinal bleeding in Scotland 2000-2015: trends in demographics, aetiology and outcomes.
    Aliment Pharmacol Ther. 2020 Nov 18. doi: 10.1111/apt.16170.
    >> Share

    September 2020
  70. LEE PL, Suk FM, Kang YN
    Letter: does tranexamic acid reduce the need for surgery in patients with upper gastrointestinal bleeding?
    Aliment Pharmacol Ther. 2020;52:1088-1089.
    >> Share

  71. MARCUS EA, Pisegna JR
    Editorial: tegoprazan-the newest advance in the management of acid-related diseases.
    Aliment Pharmacol Ther. 2020;52:1074-1075.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016